LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biochemical Basis for Broccoli's Cancer-Fighting Ability Discovered

By LabMedica International staff writers
Posted on 23 Mar 2011
Print article
Scientists are reporting discovery of a potential biochemical basis for the apparent cancer-fighting ability of broccoli and its vegetable relatives. They discovered for the first time that specific substances in the vegetables appear to target and block a defective gene associated with cancer.

The report, which could lead to new strategies for preventing and treating cancer, was published online January 11, 2011, in the American Chemical Society's (ACS) Journal of Medicinal Chemistry. Fung-Lung Chung, PhD, a professor of oncology, Lombardi Cancer Center, Georgetown University Medical Center (Washington DC, USA) and colleagues revealed in earlier research that compounds called isothiocyanates (ITCs)--found in broccoli, cauliflower, watercress, and other cruciferous vegetables--appear to stop the growth of cancer. However, nobody knew precisely how these substances work, a key to developing improved strategies for fighting cancer in humans. The tumor-suppressor gene p53 appears to play a major role in keeping cells healthy and preventing them from beginning the abnormal growth that is a hallmark of cancer. When mutated, p53 does not offer that protection, and those mutations occur in half of all human cancers. ITCs might work by targeting this gene, the report suggested.

The investigators evaluated the effects of certain naturally occurring ITCs on a variety of cancer cells, including lung, breast, and colon cancer, with and without the defective tumor-suppressor gene. They found that ITCs are capable of removing the defective p53 protein but seemingly leave the normal one alone. Drugs based on natural or custom-engineered ITCs could improve the effectiveness of current cancer treatments or lead to new strategies for treating and preventing cancer.

Related Links:

Georgetown University Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more